Francis deSouza, Illumina CEO (Photo by Kevin Dietsch/Getty Images)
September 7, 2022 08:07 AM EDT
Deals
Diagnostics

Af­ter block­ing Grail ac­qui­si­tion, EU leaves Il­lu­mi­na with few good op­tions

Jared Whitlock

Features Editor

Il­lu­mi­na on Tues­day laid out two sce­nar­ios for its $8 bil­lion Grail ac­qui­si­tion, both of which put it­self in a tough spot.

The San Diego …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times